Belatacept: Treatment of transplant rejection

Drugs of the Future

Volumn 30, Issue 9, 2005, Pages 873-876

  McIntyre, J A ^a   Fernandez D ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CD86 ANTIGEN; CREATININE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; LEA 029; LEA 29 Y; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIBODY RESPONSE; BLOOD PRESSURE; CD4+ T LYMPHOCYTE; CHO CELL; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHESUS MONKEY; RHEUMATOID ARTHRITIS; SHEEP ERYTHROCYTE; SINGLE DRUG DOSE; SURVIVAL TIME; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 30544441366     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.09.936694     Document Type: Review

References (25)

1. Allen, S.D., Rawale, S.V., Whitacre, C.C., Kaumaya, P.T.P. Therapeutic peptidomimetic strategies for autoimmune diseases: Costimulation blockade. J Pept Res 2005, 65: 591-604.
2. Sayegh, M.H., Turka, L.A. The role of T-cell costimulatory activation pathways in transplant rejection. New Engl J Med 1998, 338: 1813-21.
3. Salomon, B., Bluestone, J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001, 19: 225-52.
4. Anderson, D.E., Sharpe, A.H., Hafler, D.A. The B7-CD28/CTLA-1 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999, 11: 677-83.
5. Carreno, B.M., Collins, M. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002, 20: 29-53.
6. Vincenti, F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 2003, 55: 57-66.
7. Larsen, C.P., Pearson, T.C., Adams, A.B. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 2005, 5: 443-53.
8. Bristol-Myers Squibb reports Q2 R&D highlights. Bristol-Myers Squibb Press Release 2005, July 28.
9. Study of belatacept in subjects who are undergoing a renal transplant (NCT00114777). ClinicalTrials.gov Web Site September 7, 2005.
10. Pearson, T.C., Lin, A., Odom, K., Cowan, S., Peach, R., Haggerty, D., Larsen, C.P. Prolongation of renal allograft survival with blockade of the CD28 pathway using a novel mutant CTLA4-lg fusion protein in non-human primates. Transplant 2000 (May 13-17, Chicago) 2000, Abst 44.
11. Adams, A.B., Shirasugi, N., Durham, M.M. et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002, 51: 265-70.
12. Adams, A.B., Shirasugi, N., Durham, M.M., Rees, P. Blinder, Y., Strobert, E., Kenyon, N.S., Pearson, T.C., Larsen, C.P. LEA29Y based Edmonton Protocol protects allogeneic islets in non-human primate model. 8th Int Congr Int Pancreas Islet Transplant Assoc (June 12-15, Innsbruck) 2001, Abst O3-33.
13. Adams, A.B., Shirasugi, N., Jones, T.R. et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005, 174: 542-50.
14. Adams, A.B., Shirasugi, N., Jones, T.R., Strobert, E., Durham, M.M., Hollenbaugh, D., Haggerty, D., Townsend, R., Pearson, T.C., Larsen, C.P. Blockade of the CD40-CD154 pathway using a chimeric anti-human CD40 monoclonal antibody synergized with CD28 blockade to prolong islet allograft survival. Am J Transplant 2004, 4(Suppl. 8): Abst 486.
15. Adams, A.B., Shirasugi, N., Jones, T.R., Strobert, E.A., Durham, M.M., Hollenbuagh, D., Hagerty, D., Townsend, R., Pearson, T.C., Larsen, C.P. Blockade of the CD40-CD154 pathway using a chimeric anti-human CD40 monoclonal antibody synergizes with CD28 blockade to prolong islet allograft survival. Transplantation 2004, 78(2, Suppl.): Abst O457.
16. Vincenti, F., Larsen, C., Durrbach, A. et al. Costimulation blockade with belatacept in renal transplantation. New Engl J Med 2005, 353: 770-81.
17. Larsen, C., Durrbach, A., Nashan, B. et al. Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-Month efficacy and safety. Transplantation 2004, 78(2, Suppl.): Abst P204.
18. Vincenti, R, Muehlbacher, R, Nashan, B. etal. Co-stimulation blockade with LEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-Month efficacy and safety. Am J Transplant 2004, 4(Suppl. 8): Abst 1037.
19. Charpentier, B., Grannas, G., Pearson, T. et al. Co-stimulation blockade with LEA29Y in renal transplant: Improved renal function and CV/metabolic profile at 6 months compared with cyclosporine. Transplantation 2004, 78(2, Suppl.): Abst O214.
20. Nashan, B., Grinyo, J., Vincenti, R, Halloran, P., Hagerty, D., Zhou, W., Charpentier, B., LEA29Y Study Group. Co-stimulation blockade with LEA29Y in renal transplant: Improved renal function and CV/metabolic profile at 6 months compared with cyclosporine. Am J Transplant 2004, 4(Suppl. 8): Abst 1035.
21. Larsen, C., Charpentier, B., Wekerle, T., Blanche, G., Zhou, W., Levy, E., Vincenti, F. Calcineurin inhibitor-free immunosuppression with belatacept (LEA29Y) in renal transplant: Phase II 12-month results. Am Transpl Congr (May 21-25, Seattle) 2005, Abst 535.
22. Grinyo, J., Halloran, P., Vanrenterghem, Y., Pearson, T., Nashan, B., Sen, K., Krieger, N., Charpentier, B. Belatacept (LEA29Y) as part of a CNI-free regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss: Comparison with cyclosporine A. Am Transpl Congr (May 21-25, Seattle) 2005, Abst 946.
23. Hirose, K., Posselt, A.M., Stock, P.G., Hirose, R., Vincenti, F. Treatment of kidney transplant patients with the novel co-stimulatory blocker LEA29Y (BMS-224818) and anti-IL2 receptor antibody does not impede the development of regulatory T cells. Am J Transplant, 2004, 4(Suppl. 8): Abst 1036.
24. Moreland, L.W., Alten, R., Van den Bosch, F. et al. Costimulatory blockade in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46: 1470-9.
25. Moreland, L., Alten, R., Leon, M. et al. A multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4lg and LEA29Y administered intravenously to subjects with rheumatoid arthritis. Arthritis Rheum 2001, 44(9, Suppl.): Abst 1327.